WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory Challenges
Ouvrir ce répertoire et afficher son contenuEssential Medicines
Fermer ce répertoireSafety and Efficacy Issues
Afficher le documentSafety of HIV therapies targeted by new advisory committee
Afficher le documentThe risks and benefits of HRT
Afficher le documentMacrolides and warfarin interaction
Afficher le documentStatin risk factors: myopathy and rhabdomyolysis
Afficher le documentSerotonin syndrome
Afficher le documentAntidepressants: worsening depression and suicidal behaviour
Afficher le documentUse of SSRI antidepressants in children and adolescents
Afficher le documentRepaglinide and gemfibrozil interaction
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuHerbal Medicines
Ouvrir ce répertoire et afficher son contenuRegulatory and Safety Action
Ouvrir ce répertoire et afficher son contenuConsultation Document
Afficher le documentProposed International Nonproprietary Names: List 90
Afficher le documentRecommended International Nonproprietary Names: List 51
 

Macrolides and warfarin interaction

The Australian Drug Evaluation Committee (ADRAC) has received reports of interactions between warfarin and all four macrolide antibiotics (azithromycin, clarithromycin, erythromycin, and roxithromycin) (see table below) (1). Although most cases were asymptomatic, some reports documented substantial increases in INR. The haemorrhagic complications reported included haematoma, haemoptysis, haematuria, melaena, and retroperitoneal haemorrhage.

Close attention should be paid to INR monitoring in patients taking warfarin who are commenced on a macrolide antibiotic. Consideration could also be given to the use of an alternative antibiotic if possible. Azithromycin has a particularly long half-life (around 68 hours), so that an interaction with warfarin may theoretically persist for some days after azithromycin has been ceased.

Extracted from Australian Adverse Drug Reactions Bulletin, Volume 23, Number 2, April 2004

Reference

1. Australian Adverse Drug Reactions Bulletin, 14: 11 (1995).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013